Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

Archive ouverte

Scherpereel, Arnaud | Mazières, Julien | Greillier, Laurent | Lantuéjoul, Sylvie | Do, Pascal | Bylicki, Olivier | Monnet, Isabelle | Corre, Romain | Audigier-Valette, Clarisse | Locatelli-Sanchez, Myriam | Molinier, Olivier | Guisier, Florian | Urban, Thierry | Ligeza-Poisson, Catherine | Planchard, David | Amour, Elodie | Morin, Franck | Moro-Sibilot, Denis | Zalcman, Gérard | Debieuvre, Didier | Hiret, Sandrine | Cadranel, Jacques | Fraboulet-Moreau, Séverine | Carmier, Delphine

Edité par CCSD ; Elsevier -

International audience. There is no recommended therapy for malignant pleural mesothelioma that has progressed after first-line pemetrexed and platinum-based chemotherapy. Disease control has been less than 30% in all previous studies of second-line drugs. Preliminary results have suggested that anti-programmed cell death 1 (PD-1) monoclonal antibody could be efficacious in these patients. We thus aimed to prospectively assess the anti-PD-1 monoclonal antibody alone or in combination with anti-cytotoxic T-lymphocyte protein 4 (CTLA-4) antibody in patients with malignant pleural mesothelioma.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion